Mahtani, R.; Collin, S.M.; Tan, Z.; Shah, C.H.; Adeyemi, B.; Davies, S.; John, E.; Vidal, G.
Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Early Breast Cancer Treatment and Outcomes by Risk of Recurrence: A Retrospective US Electronic Health Records Study. Cancers 2025, 17, 1848.
https://doi.org/10.3390/cancers17111848
AMA Style
Mahtani R, Collin SM, Tan Z, Shah CH, Adeyemi B, Davies S, John E, Vidal G.
Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Early Breast Cancer Treatment and Outcomes by Risk of Recurrence: A Retrospective US Electronic Health Records Study. Cancers. 2025; 17(11):1848.
https://doi.org/10.3390/cancers17111848
Chicago/Turabian Style
Mahtani, Reshma, Simon M. Collin, Ziyu Tan, Chintal H. Shah, Basirat Adeyemi, Sophie Davies, Ellie John, and Gregory Vidal.
2025. "Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Early Breast Cancer Treatment and Outcomes by Risk of Recurrence: A Retrospective US Electronic Health Records Study" Cancers 17, no. 11: 1848.
https://doi.org/10.3390/cancers17111848
APA Style
Mahtani, R., Collin, S. M., Tan, Z., Shah, C. H., Adeyemi, B., Davies, S., John, E., & Vidal, G.
(2025). Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Early Breast Cancer Treatment and Outcomes by Risk of Recurrence: A Retrospective US Electronic Health Records Study. Cancers, 17(11), 1848.
https://doi.org/10.3390/cancers17111848
